Metabolikus szindróma gyermekés serdülokorban

Translated title of the contribution: Metabolic syndrome in childhood and adolescence

László Barkai, G. Paragh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Metabolic syndrome has an outstanding impact on public health due to its increasing prevalence and poor prognosis. The development of insulin resistance, as a consequence of obesity, can be demonstrated even in childhood which has a pivotal role in the pathomechanism of the syndrome. Besides obesity, low birth weight, increased gain in body mass in early childhood, decreased pubertal insulin sensitivity and clinical markers of insulin resistance (acanthosis nigricans, polycystic ovarian syndrome, premature adrenarche) confer risk of metabolic syndrome. Currently, there are no consistent and consensus based diagnostic criteria of metabolic syndrome in children and adolescents. The most recent definition of the International Diabetes Federation [central obesity plus any two of four factors (raised triglyceride, reduced high-density lipoprotein-cholesterol, raised blood pressure and raised fasting plasma glucose)] is not approved for childen and epidemiology data are not yet available. Applying the modified version of the most commonly used Adult Treatment Panel III diagnostic system for children and adolescents, the prevalence is given as 4.2% in the literature. As the components of the syndrome, frequency were as follows: 9.8-17.9% for abdominal obesity, 21.0-23.4% for elevated triglyceride, 18.3-23.3% for reduced high-density lipoprotein-cholesterol, 4.9-7.1 % for elevated blood pressure and 0.8-1.7% for impaired fasting glucose. High frequency of morphological and functional disturbances of the vascular and endothelial systems seen frequently among children with signs of metabolic syndrome suggests early cardiovascular events and underlines the clinical significance of this entity. The most effective tool for prevention of metabolic syndrome is to avoid the development of childhood obesity. In case of established disease, the effective treatment should address the different components of the syndrome. The authors emphasize the need of elaboration of consensus based pediatric diagnostic criteria, national prevalence data, protocols for prevention, early recognition and effective treatment.

Original languageHungarian
Pages (from-to)243-250
Number of pages8
JournalOrvosi Hetilap
Volume147
Issue number6
Publication statusPublished - Feb 12 2006

Fingerprint

Insulin Resistance
Abdominal Obesity
HDL Cholesterol
Fasting
Consensus
Triglycerides
Adrenarche
Obesity
Acanthosis Nigricans
Blood Pressure
Glucose
Polycystic Ovary Syndrome
Pediatric Obesity
Low Birth Weight Infant
Weight Gain
Blood Vessels
Epidemiology
Therapeutics
Public Health
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Metabolikus szindróma gyermekés serdülokorban. / Barkai, László; Paragh, G.

In: Orvosi Hetilap, Vol. 147, No. 6, 12.02.2006, p. 243-250.

Research output: Contribution to journalArticle

Barkai, L & Paragh, G 2006, 'Metabolikus szindróma gyermekés serdülokorban', Orvosi Hetilap, vol. 147, no. 6, pp. 243-250.
Barkai, László ; Paragh, G. / Metabolikus szindróma gyermekés serdülokorban. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 6. pp. 243-250.
@article{ee75a7dfe5c7414d9640c1b67483f1ad,
title = "Metabolikus szindr{\'o}ma gyermek{\'e}s serd{\"u}lokorban",
abstract = "Metabolic syndrome has an outstanding impact on public health due to its increasing prevalence and poor prognosis. The development of insulin resistance, as a consequence of obesity, can be demonstrated even in childhood which has a pivotal role in the pathomechanism of the syndrome. Besides obesity, low birth weight, increased gain in body mass in early childhood, decreased pubertal insulin sensitivity and clinical markers of insulin resistance (acanthosis nigricans, polycystic ovarian syndrome, premature adrenarche) confer risk of metabolic syndrome. Currently, there are no consistent and consensus based diagnostic criteria of metabolic syndrome in children and adolescents. The most recent definition of the International Diabetes Federation [central obesity plus any two of four factors (raised triglyceride, reduced high-density lipoprotein-cholesterol, raised blood pressure and raised fasting plasma glucose)] is not approved for childen and epidemiology data are not yet available. Applying the modified version of the most commonly used Adult Treatment Panel III diagnostic system for children and adolescents, the prevalence is given as 4.2{\%} in the literature. As the components of the syndrome, frequency were as follows: 9.8-17.9{\%} for abdominal obesity, 21.0-23.4{\%} for elevated triglyceride, 18.3-23.3{\%} for reduced high-density lipoprotein-cholesterol, 4.9-7.1 {\%} for elevated blood pressure and 0.8-1.7{\%} for impaired fasting glucose. High frequency of morphological and functional disturbances of the vascular and endothelial systems seen frequently among children with signs of metabolic syndrome suggests early cardiovascular events and underlines the clinical significance of this entity. The most effective tool for prevention of metabolic syndrome is to avoid the development of childhood obesity. In case of established disease, the effective treatment should address the different components of the syndrome. The authors emphasize the need of elaboration of consensus based pediatric diagnostic criteria, national prevalence data, protocols for prevention, early recognition and effective treatment.",
keywords = "Children and adolescents, Metabolic syndrome",
author = "L{\'a}szl{\'o} Barkai and G. Paragh",
year = "2006",
month = "2",
day = "12",
language = "Hungarian",
volume = "147",
pages = "243--250",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "6",

}

TY - JOUR

T1 - Metabolikus szindróma gyermekés serdülokorban

AU - Barkai, László

AU - Paragh, G.

PY - 2006/2/12

Y1 - 2006/2/12

N2 - Metabolic syndrome has an outstanding impact on public health due to its increasing prevalence and poor prognosis. The development of insulin resistance, as a consequence of obesity, can be demonstrated even in childhood which has a pivotal role in the pathomechanism of the syndrome. Besides obesity, low birth weight, increased gain in body mass in early childhood, decreased pubertal insulin sensitivity and clinical markers of insulin resistance (acanthosis nigricans, polycystic ovarian syndrome, premature adrenarche) confer risk of metabolic syndrome. Currently, there are no consistent and consensus based diagnostic criteria of metabolic syndrome in children and adolescents. The most recent definition of the International Diabetes Federation [central obesity plus any two of four factors (raised triglyceride, reduced high-density lipoprotein-cholesterol, raised blood pressure and raised fasting plasma glucose)] is not approved for childen and epidemiology data are not yet available. Applying the modified version of the most commonly used Adult Treatment Panel III diagnostic system for children and adolescents, the prevalence is given as 4.2% in the literature. As the components of the syndrome, frequency were as follows: 9.8-17.9% for abdominal obesity, 21.0-23.4% for elevated triglyceride, 18.3-23.3% for reduced high-density lipoprotein-cholesterol, 4.9-7.1 % for elevated blood pressure and 0.8-1.7% for impaired fasting glucose. High frequency of morphological and functional disturbances of the vascular and endothelial systems seen frequently among children with signs of metabolic syndrome suggests early cardiovascular events and underlines the clinical significance of this entity. The most effective tool for prevention of metabolic syndrome is to avoid the development of childhood obesity. In case of established disease, the effective treatment should address the different components of the syndrome. The authors emphasize the need of elaboration of consensus based pediatric diagnostic criteria, national prevalence data, protocols for prevention, early recognition and effective treatment.

AB - Metabolic syndrome has an outstanding impact on public health due to its increasing prevalence and poor prognosis. The development of insulin resistance, as a consequence of obesity, can be demonstrated even in childhood which has a pivotal role in the pathomechanism of the syndrome. Besides obesity, low birth weight, increased gain in body mass in early childhood, decreased pubertal insulin sensitivity and clinical markers of insulin resistance (acanthosis nigricans, polycystic ovarian syndrome, premature adrenarche) confer risk of metabolic syndrome. Currently, there are no consistent and consensus based diagnostic criteria of metabolic syndrome in children and adolescents. The most recent definition of the International Diabetes Federation [central obesity plus any two of four factors (raised triglyceride, reduced high-density lipoprotein-cholesterol, raised blood pressure and raised fasting plasma glucose)] is not approved for childen and epidemiology data are not yet available. Applying the modified version of the most commonly used Adult Treatment Panel III diagnostic system for children and adolescents, the prevalence is given as 4.2% in the literature. As the components of the syndrome, frequency were as follows: 9.8-17.9% for abdominal obesity, 21.0-23.4% for elevated triglyceride, 18.3-23.3% for reduced high-density lipoprotein-cholesterol, 4.9-7.1 % for elevated blood pressure and 0.8-1.7% for impaired fasting glucose. High frequency of morphological and functional disturbances of the vascular and endothelial systems seen frequently among children with signs of metabolic syndrome suggests early cardiovascular events and underlines the clinical significance of this entity. The most effective tool for prevention of metabolic syndrome is to avoid the development of childhood obesity. In case of established disease, the effective treatment should address the different components of the syndrome. The authors emphasize the need of elaboration of consensus based pediatric diagnostic criteria, national prevalence data, protocols for prevention, early recognition and effective treatment.

KW - Children and adolescents

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=33646189622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646189622&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 243

EP - 250

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 6

ER -